Aficamten resulted in a significantly greater improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score compared to metoprolol at 24 weeks (adjusted difference +7.8 points).
Does aficamten improve patient-reported health status compared to metoprolol as first-line therapy in symptomatic obstructive hypertrophic cardiomyopathy?
Aficamten provided superior improvements in patient-reported health status compared to metoprolol in symptomatic obstructive hypertrophic cardiomyopathy, challenging the established practice of using beta-blockers as first-line therapy.
Effect estimate: Difference +7.8 points
p-value: p=<0.001
Aficamten vs Metoprolol: A Turning Point in Obstructive Hypertrophic Cardiomyopathy Care?: The MAPLE-HCM Results Heidecker, Bettina; Olivotto, Iacopo 2026 Abstract Rather than just establishing a superiority in controlling symptoms and gradients, great expectations lie in the demonstration that myosin inhibitors may be true modifiers of the long-term trajectory of disease.
Heidecker et al. (Wed,) conducted a editorial in Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) (n=175). Aficamten vs. Metoprolol was evaluated on Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS) improvement (Difference +7.8 points, p=<0.001). Aficamten resulted in a significantly greater improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score compared to metoprolol at 24 weeks (adjusted difference +7.8 points).